Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis.
D'Oliveira Júnior
A
A
Serviço de Imunologia, Hospital Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Machado
P R
PR
Carvalho
E M
EM
D000293:Adolescent; D000328:Adult; D000493:Allopurinol / Q000009:adverse effects / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001938:Brazil / Q000453:epidemiology; D002648:Child; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000453:epidemiology; D008536:Meglumine / Q000627:therapeutic use; D008875:Middle Aged; D009092:Mucous Membrane / Q000473:pathology; D016896:Treatment Outcome; D014456:Ulcer / Q000139:chemically induced; D014527:Uric Acid / Q000097:blood
D000964:Antimetabolites, Antineoplastic; D014527:Uric Acid; D000493:Allopurinol; D008536:Meglumine